Epizyme to Present at the Wedbush PacGrow 2019 Healthcare Conference
Epizyme, Inc. (Nasdaq:EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that Robert Bazemore, president and chief executive officer, will present at the Wedbush PacGrow 2019 Healthcare Conference on Tuesday, Aug. 13, 2019 at 10:55 a.m. ET in New York City.
A live webcast will be available in the investor section of the company's website at www.epizyme.com. The webcast will be archived for 60 days following the presentation.
About Epizyme, Inc.
Epizyme, Inc. is a late-stage biopharmaceutical company committed to rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. Epizyme is broadly developing its lead product candidate, tazemetostat, a first-in-class EZH2 inhibitor, with studies underway in both solid tumors and hematological malignancies, as a monotherapy and combination therapy in relapsed and front-line disease. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them. For more information, visit www.epizyme.com.
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland.
The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance --
2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme").
For this purpose, Sobi has prepared a base prospectus, which...
